Please try another search
Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. Kancera AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Erik Nerpin | 62 | 2010 | Independent Chairman of the Board |
Thomas Olin | 65 | 2010 | Executive VP, CSO & Director |
Carl-Henrik Heldin | 71 | 2012 | Independent Director |
Petter Brodin | 41 | 2021 | Independent Director |
Håkan Mellstedt | 81 | 2010 | Independent Director |
Charlotte Edenius | 65 | 2016 | Independent Director |
Anders Gabrielsen | 57 | 2018 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review